

# Mercia CMV TA

## M502

Microgen Bioproducts Ltd.  
1 Admiralty Way,  
Camberley,  
Surrey. GU15 3DT  
United Kingdom



Telephone +44 (0)1276 600081  
Telefax +44 (0)1276 600151

[www.microgenbioproducts.com](http://www.microgenbioproducts.com)

**Mercia CMV-TA** has been developed in response to the need for increased sensitivity in detection of early seroconversion from negative to positive antibody status. Early detection is important in the management of blood donations destined for antibody-negative recipients and in the management of transplant recipients and other immunocompromised patients.

**Mercia CMV-TA** is a sensitive competitive enzyme immunoassay for the *in vitro* detection of IgG and IgM antibodies to cytomegalovirus in human serum or plasma samples.

CMV antigen is coated on the wells of microtitre plates. Samples are added to the plate immediately followed by peroxidase-conjugated monoclonal antibody to CMV.

During this first incubation any CMV-specific antibodies present in the sample will compete with the conjugated antibody for the CMV antigen on the wells.

After washing the presence of bound enzyme is visualised using the substrate TMB/peroxide to produce a coloured end-product.

The intensity of the colour is inversely proportional to the amount of CMV antibodies present in the sample.

Human CMV belongs to the Herpes virus group and can cause latent infections. The majority of individuals are infected with CMV at some time during their lives with infection, reinfection or reactivation being asymptomatic in normal adults and children.

In circumstances where the immune system is immature (foetus and neonate) or compromised (allograft recipients, AIDS patients) CMV infection can have severe implications.



- Suitable for serum and plasma
- Flexible 8 well strip format
- Total antibody capture – ideal for CMV antibody screening
- Colour coded reagents and ready-to-use controls.
- Earlier detection of seroconversion
- Excellent discrimination between positives and negatives
- Suitable for automation.
- Assay time < 2 ½ hours.

<b>Code</b>	M502
<b>Description</b>	Mercia CMV TA
<b>Size</b>	480T
<b>Storage</b>	2-8°C



## Comparison of Mercia CMV-TA and an NBA<sup>†</sup> Approved Assay

		Mercia CMV-TA		
		Positive	Negative	Total
Approved CMV-TA	Positive	85	2*	87
	Negative	1*	62	63
Total		86	64	150

\*: True CMV status not fully established

BBI Panel Sero-conversion	Approved CMV-TA	Native IgG + IgM	Recombinant IgG	Mercia CMV-TA
PTC901- 1	0.60	0.31	0.88	0.71
2	0.55	0.28	0.81	0.71
3	0.60	0.29	0.67	1.19
4	0.61	0.35	0.92	1.45
5	0.76	0.93	2.25	3.24
6	1.26	3.27	9.19	9.09
7	2.47	3.08	9.19	22.30
8	4.29	4.44	9.19	30.67
9	6.58	4.18	9.19	33.46
BBI CMV Low titre Panel	Approved CMV-TA	Native IgG + IgM	Recombinant IgG	Mercia CMV-TA
PTC202- 1	4.56	3.6	9.19	40.74
2	12.49	2.67	9.19	22.11
3	6.43	3.28	9.19	23.45
4	18.54	2.75	6.78	51.6
5	10.26	3.4	9.19	32.25
6	0.66	0.24	0.55	1.08
7	13.71	2.14	9.19	1.51
8	18.54	3.14	9.19	9.68
9	18.37	4.09	9.19	48.38
10	11.6	4.09	9.19	40.74
11	1.35	1.71	2.56	13.82
12	14.21	1.77	7.35	0.85
13	14.82	3.6	9.19	40.74
14	17.95	2.13	5.17	13.58
15	17.47	2.87	9.19	19.35
16	19.78	2.33	9.19	8.9
17	22.88	5.93	9.19	36.86
18	6.69	2.59	9.19	40.74
19	11.7	3.17	9.19	19.85
20	20.12	3.09	9.19	25.8
21	21.35	4.53	9.19	14.6
22	10.14	3.58	8.54	12.69
23	19.12	5.76	9.19	40.74
24	0.63	0.23	0.36	0.83
25	15.64	3.53	9.19	33.65

Results in Antibody Index

	Negative
	Equivocal
	Positive

<sup>†</sup> UK National Blood Authority